|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We searched all eligible published studies based on the association between codon 72 of the p53 Arg>Pro polymorphism and risk of OC.
|
24747975 |
2014 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to validate the use of PCR-RFLP techniques for the evaluation of p53 codon 72 and CYP1A1 gene polymorphisms in relation with ovarian cancer in a Romanian population and to evaluate gene-environment interaction in this context.
|
22395499 |
2012 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
|
27179933 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Oncomorphic TP53 mutations were present in 21.3% of ovarian cancers in the TCGA dataset.
|
25385265 |
2015 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively.
|
20514505 |
2010 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
40 out of 63 (G2/3) patients with G2/3 OC showed mutant p53 and 23 patients showed a wild-type pattern. p53 status was significantly different between these two groups (LMP/G1 vs. G2/3) (P = 0.015).
|
19609560 |
2010 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The early stages of this disease are asymptomatic and more than 75% of the cases are diagnosed with regional or distant metastases. p53 gene is frequently mutated in some histological subtypes of ovarian carcinomas.
|
20414935 |
2010 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Laser-capture microdissected and polymerase chain reaction-amplified DNA revealed reproducible p53 mutations in eight of 14 fully-analysed p53 signatures and all of the 12 TICs; TICs and their associated ovarian carcinomas shared identical mutations.
|
17117391 |
2007 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An abundance of p53 null mutations in ovarian carcinoma.
|
8700537 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
P5091 shows efficacy in suppressing ovarian cancers harbouring wild-type and mutant p53.
|
29049989 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region.
|
19276375 |
2009 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.
|
8679443 |
1996 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ovarian cancers with a p53 null mutation are more likely to lack telomerase activity.
|
12496479 |
2003 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Resistance to chemotherapy and high heterogeneity in mutations contribute to ovarian cancer's lethality, including many mutations in tumor suppressor p53.
|
31039796 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
|
16793127 |
2006 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A 42-core tissue microarray, which included the 5 major histotypes of ovarian carcinomas with a subset having known TP53 mutational status, was used for this Canadian Immunohistochemistry Quality Control challenge.
|
26598982 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations.
|
24218521 |
2014 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Alterations in p53 were detected in 48% of chicken ovarian cancers.
|
19174584 |
2009 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In sequential PBMC samples harvested from 13 patients with OC near diagnosis and after a median of 2 different chemotherapy regimens, somatic mosaic PPM1D mutations increased in 11 individuals (84.6%) and TP53 mutations appeared in 2 (15.4%).
|
26847329 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Using polymerase chain reaction/single strand conformational polymorphism, DNA sequencing, and immunohistochemistry, 11 ovarian carcinomas (48%) demonstrated a p53 mutation.
|
8319218 |
1993 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Besides p53DeltaE6 and p53beta, we identified p53zeta, p53delta and p53varepsilon, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032).
|
20101229 |
2010 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutant p53 is frequently detected in endometrial and ovarian carcinoma, but it is rare in cervical cancers.
|
9546366 |
1998 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A possible functional impairment of the p53 pathway caused by the G/G genotype of the MDM2 SNP309 may modify the association between p53 mutational status and prognosis in ovarian cancer.
|
22134502 |
2012 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes.
|
17292821 |
2007 |